|
1
|
Kademani D: Oral cancer. Mayo Clin Proc.
82:878–887. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petersen PE: The world oral health report
2003: Continuous improvement of oral health in the 21st century-the
approach of WHO global oral programme. Community Dent Oral
Epidemiol. 31:3–23. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chinn SB and Myers JN: Oral cavity
carcinoma: Current management, controversies, and future
directions. J Clin Oncol. 33:3269–3276. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines®) Head and Neck Cancers. Version 2. 2020.
|
|
6
|
Zhong LP and Zhang ZY: Neoadjuvant versus
induction chemotherapy: More than semantics reply. J Clin Oncol.
31:2972–2973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Posner RM, Hershock MD, Blajman RC,
Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM,
Cullen K, Ervin TJ, et al: Cisplatin and fluorouracil alone or with
docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vermorken BJ, Remenar E, Van HerpenC,
Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss
JH, et al: Cisplatin, fluorouracil, and docetaxel in unresectable
head and neck cancer. N Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong LP, Zhang CP, Ren GX, Guo W, William
WN Jr, Sun J, Zhu HG, Tu WY, Li J, CaI YL, et al: Randomized phase
III trial of induction chemotherapy with docetaxel, cisplatin, and
fluorouracil followed by surgery versus up-front surgery in locally
advanced resectable oral squamous cell carcinoma. J Clin Oncol.
31:744–751. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhong LP, Zhang CP, Ren GX, Guo W, William
WN Jr, Sun J, Hong CS, Zhu HG, Tu WY, Li J, et al: Long-Term
results of a randomized phase III trial of TPF induction
chemotherapy followed by surgery and radiotherapy in locally
advanced oral squamous cell carcinoma. Oncotarget. 6:18707–18714.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhong LP, Zhu DW, William WN Jr, Liu Y, Ma
J, Yang CZ, Yang X, Wang LZ, Li J, Myers JN, et al: Elevated cyclin
D1 expression is predictive for a benefit from TPF induction
chemotherapy in oral squamous cell carcinoma patients with advanced
nodal disease. Mol Cancer Ther. 12:1112–1121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sherr CJ, Beach D and Shapiro GI:
Targeting CDK4 and CDK6: From discovery to therapy. Cancer Discov.
6:353–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramos-García P, Gil-Montoya JA, Scully C,
Ayén A, González-Ruiz L, Navarro-Triviño FJ and González-Moles MA:
An update on the implications of cyclin D1 in oral carcinogenesis.
Oral Dis. 23:897–912. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hardisson D: Molecular pathogenesis of
head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol.
260:502–508. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Capaccio P, Pruneri G, Carboni N, Pagliari
AV, Quatela M, Cesana BM and Pignataro L: Cyclin D1 expression is
predictive of occult metastases in head and neck cancer patients
with clinically negative cervical lymph nodes. Head Neck.
22:234–240. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang SF, Cheng SD, Chuang WY, Chen IH,
Liao CT, Wang HM and Hsieh LL: Cyclin D1 overexpression and poor
clinical outcomes in Taiwanese oral cavity squamous cell carcinoma.
World J Surg Oncol. 10:402012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Akervall J, Kurnit DM, Adams M, Zhu S,
Fisher SG, Bradford CR and Carey TE: Overexpression of cyclin D1
correlates with sensitivity to cisplatin in squamous cell carcinoma
cell lines of the head and neck. Acta Otolaryngol. 124:851–857.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Warenius HM, Seabra LA and Maw P:
Sensitivity to cis-diamminedichloroplatinum in human cancer cells
is related to expression of cyclin D1 but not c-raf-1 protein. Int
J Cancer. 67:224–231. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakashima T and Clayman GL: Antisense
inhibition of cyclin D1 in human head and neck squamous cell
carcinoma. Arch Otolaryngol Head Neck Surg. 126:957–961. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kothari V and Mulherkar R: Inhibition of
cyclin D1 by shRNA is associated with enhanced sensitivity to
conventional therapies for head and neck squamous cell carcinoma.
Anticancer Res. 32:121–128. 2012.PubMed/NCBI
|
|
21
|
Zhong LP, Pan HY, Zhou XJ, Ye DX, Zhang L,
Yang X, Chen WT and Zhang ZY: Characteristics of a cancerous cell
line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human
immortalized oral epithelial cell line. Arch Oral Biol. 53:443–452.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mineta H, Miura K, Takebayashi S, Ueda Y,
Misawa K, Harada H, Wennerberg J and Dictor M: Cyclin D1
overexpression correlates with poor prognosis in patients with
tongue squamous cell carcinoma. Oral Oncol. 36:194–198. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bova RJ, Quinn DI, Nankervis JS, Cole IE,
Sheridan BF, Jensen MJ, Morgan GJ, Hughes CJ and Sutherland RL:
Cyclin D1 and p16INK4A expression predict reduced survival in
carcinoma of the anterior tongue. Clin Cancer Res. 5:2810–2819.
1999.PubMed/NCBI
|
|
24
|
Zhong LP, Wei KJ, Yang X, Pan HY, Wang LZ
and Zhang ZY: Overexpression of galectin-1 is positively correlated
with pathologic differentiation grade in oral squamous cell
carcinoma. J Cancer Res Clin Oncol. 136:1527–1535. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gioanni J, Fischel JL, Lambert JC, Demard
F, Mazeau C, Zanghellini E, Ettore F, Formento P, Chauvel P and
Lalanne CM: Two new human tumor cell lines derived from squamous
cell carcinomas of the tongue: Establishment, characterization and
response to cytotoxic treatment. Eur J Cancer Clin Oncol.
24:1445–1455. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dozier C, Mazzolini L, Cénac C, Froment C,
Burlet-Schiltz O, Besson A and Manenti S: CyclinD-CDK4/6 complexes
phosphorylate CDC25A and regulate its stability. Oncogene.
36:3781–3788. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhong Z, Yeow WS, Zou C, Wassell R, Wang
C, Pestell RG, Quong JN and Quong AA: Cyclin D1/cyclin-dependent
kinase 4 interacts with filamin A and affects the migration and
invasion potential of breast cancer cells. Cancer Res.
70:2105–2114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qie S and Diehl JA: Cyclin D1, cancer
progression, and opportunities in cancer treatment. J Mol Med
(Berl). 94:1313–1326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sales KU, Giudice FS, Castilho RM, Salles
FT, Squarize CH, Abrahao AC and Pinto DS Jr: Cyclin D1-induced
proliferation is independent of beta-catenin in head and neck
cancer. Oral Dis. 20:e42–e48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fusté NP, Fernández-Hernández R, Cemeli T,
Mirantes C, Pedraza N, Rafel M, Torres-Rosell J, Colomina N,
Ferrezuelo F, Dolcet X and Garí E: Cytoplasmic cyclin D1 regulates
cell invasion and metastasis through the phosphorylation of
paxillin. Nat Commun. 7:115812016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN,
Neskey DM and Zhong LP: Induction chemotherapy decreases the rate
of distant metastasis in patients with head and neck squamous cell
carcinoma but does not improve survival or locoregional control: A
meta-analysis. Oral Oncol. 48:1076–1084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pignon JP, le Maître A, Maillard E and
Bourhis J; MACH-NC Collaborative Group, : Meta-Analysis of
chemotherapy in head and neck cancer (MACH-NC): An update on 93
randomised trials and 17,346 patients. Radiother Oncol. 92:4–14.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jamieson ER and Lippard SJ: Structure,
recognition, and processing of cisplatin-DNA adducts. Chem Rev.
99:2467–2498. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Longley DB, Harkin DP and Johnson PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Garcia P, Braguer D, Carles G, el Khyari
S, Barra Y, de Ines C, Barasoain I and Briand C: Comparative
effects of taxol and Taxotere on two different human carcinoma cell
lines. Cancer Chemother Pharmacol. 34:335–343. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Perisanidis C, Perisanidis B, Wrba F,
Brandstetter A, El Gazzar S, Papadogeorgakis N, Seemann R, Ewers R,
Kyzas PA and Filipits M: Evaluation of immunohistochemical
expression of p53, p21, p27, cyclin D1, and Ki67 in oral and
oropharyngeal squamous cell carcinoma. J Oral Pathol Med. 41:40–46.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pirkmaier A, Yuen K, Hendley J, O'Connell
MJ and Germain D: Cyclin d1 overexpression sensitizes breast cancer
cells to fenretinide. Clin Cancer Res. 9:1877–1884. 2003.PubMed/NCBI
|
|
38
|
Cowan AJ, Frayo SL, Press OW,
Palanca-Wessels MC, Pagel JM, Green DJ and Gopal AK: Bortezomib and
fenretinide induce synergistic cytotoxicity in mantle cell lymphoma
through apoptosis, cell-cycle dysregulation, and IκBα kinase
downregulation. Anticancer Drugs. 26:974–983. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Smith ME, Das BC and Kalpana GV: In vitro
activities of novel 4-HPR derivatives on a panel of rhabdoid and
other tumor cell lines. Cancer Cell Int. 11:342011. View Article : Google Scholar : PubMed/NCBI
|
